JP5661791B2 - Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 - Google Patents

Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 Download PDF

Info

Publication number
JP5661791B2
JP5661791B2 JP2012541257A JP2012541257A JP5661791B2 JP 5661791 B2 JP5661791 B2 JP 5661791B2 JP 2012541257 A JP2012541257 A JP 2012541257A JP 2012541257 A JP2012541257 A JP 2012541257A JP 5661791 B2 JP5661791 B2 JP 5661791B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
substituted
saturated heterocyclic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012541257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522165A5 (enExample
JP2013522165A (ja
Inventor
潤美 丸山
潤美 丸山
尚也 木ノ村
尚也 木ノ村
俊 野島
俊 野島
昌弘 高村
昌弘 高村
慶介 柿口
慶介 柿口
嘉人 畳谷
嘉人 畳谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Priority to JP2012541257A priority Critical patent/JP5661791B2/ja
Publication of JP2013522165A publication Critical patent/JP2013522165A/ja
Publication of JP2013522165A5 publication Critical patent/JP2013522165A5/ja
Application granted granted Critical
Publication of JP5661791B2 publication Critical patent/JP5661791B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2012541257A 2010-03-11 2011-03-11 Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 Expired - Fee Related JP5661791B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012541257A JP5661791B2 (ja) 2010-03-11 2011-03-11 Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2010054177 2010-03-11
JP2010054177 2010-03-11
JP2010285844 2010-12-22
JP2010285844 2010-12-22
JP2012541257A JP5661791B2 (ja) 2010-03-11 2011-03-11 Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩
PCT/JP2011/056497 WO2011111875A1 (en) 2010-03-11 2011-03-11 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof

Publications (3)

Publication Number Publication Date
JP2013522165A JP2013522165A (ja) 2013-06-13
JP2013522165A5 JP2013522165A5 (enExample) 2014-03-13
JP5661791B2 true JP5661791B2 (ja) 2015-01-28

Family

ID=44563664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541257A Expired - Fee Related JP5661791B2 (ja) 2010-03-11 2011-03-11 Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩

Country Status (9)

Country Link
US (1) US8541585B2 (enExample)
EP (1) EP2545046A4 (enExample)
JP (1) JP5661791B2 (enExample)
KR (1) KR101756495B1 (enExample)
CN (1) CN102884059B (enExample)
AU (1) AU2011225095C1 (enExample)
CA (1) CA2792539C (enExample)
TW (1) TWI475015B (enExample)
WO (1) WO2011111875A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
PL245933B1 (pl) 2014-07-04 2024-11-04 Inst Farmakologii Polskiej Akademii Nauk (Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
PE20232046A1 (es) 2020-12-17 2023-12-27 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
FR2285883A1 (fr) 1974-09-30 1976-04-23 Cerm Cent Europ Rech Mauvernay Nouveaux composes chimiques a activite bronchospasmolytique et antitussive, et procede pour leur obtention
AU5292393A (en) 1992-10-07 1994-04-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
JP3162572B2 (ja) 1993-04-28 2001-05-08 住友製薬株式会社 インドロイルグアニジン誘導体
JPH08208602A (ja) 1994-10-18 1996-08-13 Sumitomo Pharmaceut Co Ltd インドロイルグアニジン誘導体
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
UA58476C2 (uk) 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
WO2002085890A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
MXPA04005988A (es) 2001-12-19 2004-09-27 Lundbeck & Co As H 3,4-dihidro-1h-isoquinolin-2-il-derivados.
WO2005066165A1 (en) 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
EP1797072A4 (en) 2004-09-17 2009-09-09 Exelixis Inc PYRAZOLKINASE MODULATORS AND USE METHOD
CA2628527A1 (en) 2005-11-17 2007-05-31 Arena Pharmaceuticals, Inc. Modulators of the h3 receptor useful for the treatment of disorders related thereto
JP5176281B2 (ja) 2006-03-23 2013-04-03 大日本印刷株式会社 リチウムイオン電池

Also Published As

Publication number Publication date
CA2792539C (en) 2017-04-18
KR20130016234A (ko) 2013-02-14
AU2011225095C1 (en) 2017-01-19
EP2545046A1 (en) 2013-01-16
AU2011225095A1 (en) 2012-09-27
EP2545046A4 (en) 2015-03-25
WO2011111875A1 (en) 2011-09-15
KR101756495B1 (ko) 2017-07-10
US8541585B2 (en) 2013-09-24
AU2011225095B2 (en) 2016-05-19
CN102884059B (zh) 2015-08-26
TWI475015B (zh) 2015-03-01
CN102884059A (zh) 2013-01-16
CA2792539A1 (en) 2011-09-15
JP2013522165A (ja) 2013-06-13
TW201139413A (en) 2011-11-16
US20120214790A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
JP5661791B2 (ja) Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩
CN113557235A (zh) 用于药物治疗的杂环化合物
TW201311674A (zh) 吲唑－及吡咯并吡啶－衍生物及其醫藥用途
CN102239168B (zh) 作为h3调节剂的取代的哌啶螺吡咯烷酮和哌啶酮
JP7253086B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
CN112673001B (zh) 作为激酶抑制剂的吲唑甲酰胺
WO2001070689A1 (en) DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS
IL303942A (en) An aromatic heterocyclic substance, a pharmaceutical composition comprising the same, and their use
CA3234429A1 (en) Ras inhibitors, compositions and methods of use thereof
JP5715605B2 (ja) Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩からなる医薬
JP2014506905A (ja) 新規なベンゾジオキソールピペリジン化合物
JPWO2013039057A1 (ja) ピロリジン−３−イル酢酸誘導体
KR101575703B1 (ko) 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체
JP2009523747A (ja) α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用
WO2019129025A1 (zh) 四氢吡咯类化合物、其制备方法、药物组合物及用途
JP2013523806A (ja) スルタム化合物
US20080015214A1 (en) 3-piperidin-4-yl-indole orl-1 receptor modulators
CN101243075A (zh) 新颖的2,3-二氢吲哚化合物
CN118076599A (zh) 二噁嗪类及其在治疗gba相关疾病中的用途
CN120112526A (zh) 一种egfr降解剂及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141203

R150 Certificate of patent or registration of utility model

Ref document number: 5661791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees